Therapeutic potential of bevacizumab (Avastin) in herpetic stromal keratitis (HSK)

Medical Hypotheses

Volumn 69, Issue 3, 2007, Pages 568-570

  Hosseini, Hamid ^a   Khalili, Mohammad Reza ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; BEVACIZUMAB; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CORNEA NEOVASCULARIZATION; GENE EXPRESSION; HERPES SIMPLEX KERATITIS; HERPES SIMPLEX VIRUS 1; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SCAR FORMATION; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CORNEA; HERPESVIRIDAE; HUMANS; KERATITIS, HERPETIC; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

SIMPLEXVIRUS;

EID: 34447258889     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2007.01.032     Document Type: Article

References (16)

1. Green L.K., and Pavan-Langston D. Herpes simplex ocular inflammatory disease. Int Ophthalmol Clin 46 2 (2006) 27-37
2. Pepose J.S., Holland G.N., and Wilhelmus K.R. Ocular infection and immunity (1996), Mosby, St. Louis
3. Kaye S., and Choudhary A. Herpes simplex keratitis. Prog Retin Eye Res 25 4 (2006) 355-380
4. Zheng M., Deshpande S., Lee S., Ferrara N., and Rouse B.T. Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis. J Virol 75 20 (2001) 9828-9835
5. Zheng M., Schwarz M.A., Lee S., Kumaraguru U., and Rouse B.T. Control of stromal keratitis by inhibition of neovascularization. Am J Pathol 159 3 (2001) 1021-1029
6. Kim B., Lee S., Suvas S., and Rouse B.T. Application of plasmid DNA encoding IL-18 diminishes development of herpetic stromal keratitis by antiangiogenic effects. J Immunol 175 1 (2005) 509-516
7. Klinman D.M., Zheng M., Gierynska M., and Rouse B.T. DNA containing bioactive CpG motifs promote angiogenesis. Drug News Perspect 15 6 (2002) 358-363
8. Zheng M., Klinman D.M., Gierynska M., and Rouse B.T. DNA containing CpG motifs induces angiogenesis. Proc Nat Acad Sci USA 99 13 (2002) 8944-8949
9. Hosseini H., and Nejabat M. A potential therapeutic strategy for inhibition of corneal neovascularization with new anti-VEGF agents. Med Hypotheses November (2006)
10. Ferrara N., Hillan K.J., Gerber H.P., and Novotny W. Discovery development of bevacizumab an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3 5 (2004) 391-400
11. Aisenbrey S., Ziemssen F., Volker M., Gelisken F., Szurman P., Jaissle G., et al. Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol December (2006)
12. Iliev M.E., Domig D., Wolf-Schnurrbursch U., Wolf S., and Sarra G.M. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 142 6 (2006) 1054-1056
13. Jorge R., Costa R.A., Calucci D., Cintra L.P., and Scott I.U. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina 26 9 (2006) 1006-1013
14. Jorge R., Costa R.A., Calucci D., and Scott I.U. Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis. Graefes Arch Clin Exp Ophthalmol November (2006)
15. Manzano R., Peyman G., Khan P., Carvounis P., Kivilcim M., Ren M., et al. Inhibition of experimental corneal neovascularization by bevacizumab (Avastin). Br J Ophthalmol December (2006)
16. Philipp W., Speicher L., and Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci 41 9 (2000) 2514-2522